Vera Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
VERA$30.61+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities | ||
| Net loss | $(95,990) | $(89,056) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation, amortization and accretion | (4,086) | (846) |
| Reduction in the carrying amount of operating lease right-of-use assets | 2,224 | 2,271 |
| Stock-based compensation | 11,493 | 8,887 |
| Issuance of Class A common stock for licensing payment, net of costs | — | 3,592 |
| Change in fair value of non-marketable equity securities | 47 | 809 |
| Changes in operating assets and liabilities: | ||
| Prepaid expense and other current assets | 173 | (8,182) |
| Other assets | (309) | (111) |
| Accounts payable | (873) | 10,606 |
| Accrued and other current liabilities | (2,215) | 7,036 |
| Operating lease liabilities | (2,645) | (2,602) |
| Net cash used in operating activities | (92,181) | (67,596) |
| Cash flows from investing activities | ||
| Purchase of property and equipment | (63) | (62) |
| Purchase of marketable securities | (224,930) | (148,490) |
| Proceeds from maturities of marketable securities | 176,019 | 78,000 |
| Proceeds from sale of marketable securities | 9,543 | — |
| Net cash used in investing activities | (39,431) | (70,552) |
| Cash flows from financing activities | ||
| Proceeds from exercise of stock options and employee stock purchase plan | 1,056 | 2,083 |
| Proceeds from borrowings, net of costs | 24,741 | 19,816 |
| Proceeds from issuance of Class A common stock in follow-on offering | 115,000 | 86,131 |
| Payment of costs and underwriting discounts and commissions related to follow-on offering | (7,256) | (6,097) |
| Net cash provided by financing activities | 133,541 | 101,933 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 1,929 | (36,215) |
| Cash, cash equivalents and restricted cash, beginning of year | 43,752 | 79,967 |
| Cash, cash equivalents and restricted cash, end of year | $45,681 | $43,752 |
| Reconciliation of cash and cash equivalents and restricted cash to the balance sheets | ||
| Cash and cash equivalents | 45,681 | 43,459 |
| Restricted cash | — | 293 |
| Total cash and cash equivalents and restricted cash | $45,681 | $43,752 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $3,352 | $895 |
| Cash paid for operating leases | $3,000 | $2,734 |
| Issuance of Class A common stock in payment of licensing fees | $— | $2,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.